Associate Professor of Medicine, Dana-Farber Cancer Institute
Hematology
Dr. Nikhil C. Munshi, MD
|
|
Give Review
Doctor Nikhil C. Munshi, MD is an expert in the field of Hematology. He went to Indiana University School of Medicine. Indiana University School of Medicine has a rank of 45 in research and a 47 in primary care He received awards:"Super Doctor". Nikhil Munshi is a published doctor as well. He has 100 publications published. The latest was: Deficiency of IL-17A, but not the prototypical Th17 transcription factor RORt, decreases murine spontaneous intestinal tumorigenesis. He accepts Medicare payments and is listed with Medicare.gov.
Publications
- Association of Agent Orange With Plasma Cell Disorder: Further Evidence.
- Deficiency of IL-17A, but not the prototypical Th17 transcription factor RORγt, decreases murine spontaneous intestinal tumorigenesis.
- Selective targeting of IRF4 by synthetic microRNA-125b-5p mimics induces anti-multiple Myeloma activity in vitro and in vivo.
- A Phase II trial of weekly bortezomib and dexamethasone in veterans with newly diagnosed multiple myeloma not eligible for or who deferred autologous stem Cell transpl...
- Role of additional chromosomal changes in the prognostic value of t(4;14) and del(17p) in multiple Myeloma: the IFM experience.
- Genetics of multiple Myeloma: another heterogeneity level?
- Patient-reported Outcomes for Multicentric Castleman's Disease in a Randomized, Placebo-controlled Study of Siltuximab.
- Multimodality imaging and clinical features in Castleman disease: single institute experience in 30 patients.
- Targeting PD1-PDL1 immune checkpoint in plasmacytoid dendritic Cell interactions with T Cells, natural killer Cells and multiple myeloma Cells.
- Antitumor activities of selective HSP90α/β inhibitor, TAS-116, in combination with bortezomib in multiple Myeloma.
- Immunotherapy Strategies in Multiple Myeloma.
- Pyk2 promotes tumor progression in multiple Myeloma.
- Differential and limited expression of mutant alleles in multiple Myeloma.
- Use of a claims database to characterize and estimate the incidence rate for Castleman disease.
- Treatment recommendations for patients with Waldenström's Macroglobulinemia (WM) and related Disorders: consensus from the Seventh International Workshop on WM.
- Biomarkers of Bone Remodeling in Multiple Myeloma Patients to Tailor Bisphosphonate Therapy.
- CSNK1α1 mediates malignant plasma Cell survival.
- Management of Posterior Reversible Encephalopathy Syndrome Induced by Carfilzomib in a Patient With Multiple Myeloma.
- A multiepitope of XBP1, CD138 and CS1 peptides induces myeloma-specific cytotoxic T lymphocytes in T Cells of smoldering myeloma patients.
- Transcription factor-pathway coexpression analysis reveals cooperation between SP1 and ESR1 on dysregulating Cell cycle arrest in non-hyperdiploid multiple myeloma.
- Outcomes in patients with relapsed or refractory multiple Myeloma in a phase I study of everolimus in combination with lenalidomide.
- Gene expression profile alone is inadequate in predicting complete response in multiple Myeloma.
- MRI features of extramedullary Myeloma.
- MYD88-independent growth and survival effects of Sp1 transactivation in Waldenstrom's Macroglobulinemia.
- Immunotherapy for multiple Myeloma.
- Novel afucosylated anti-B Cell maturation antigen-monomethyl auristatin F antibody-drug conjugate (GSK2857916) induces potent and selective anti-multiple myeloma activ...
- IMWG consensus on risk stratification in multiple Myeloma.
- A phase II trial of lenalidomide, bortezomib and dexamethasone in patients with relapsed and relapsed/refractory Myeloma.
- Lenalidomide Causes Selective Degradation of IKZF1 and IKZF3 in Multiple Myeloma Cells.
- Biology of telomeres: importance in etiology of esophageal Cancer and as therapeutic target.
- Phase transitions in human IgG solutions.
- Histone deacetylase 3 (HDAC3) as a novel therapeutic target in multiple Myeloma.
- Identification of human leucocyte antigen (HLA)-A*0201-restricted cytotoxic T lymphocyte epitopes derived from HLA-DOβ as a novel target for multiple Myeloma.
- Vaccination with Dendritic Cell/Tumor Fusions following Autologous Stem Cell Transplant Induces Immunologic and Clinical Responses in Multiple Myeloma Patients.
- New strategies in the treatment of multiple Myeloma.
- Minimal residual disease in multiple Myeloma.
- Small-molecule multi-targeted kinase inhibitor RGB-286638 triggers P53-dependent and -independent anti-multiple Myeloma activity through inhibition of transcriptional ...
- In Vitro and In Vivo Antitumor Activity of a Novel Alkylating Agent, Melphalan-Flufenamide, against Multiple Myeloma Cells.
- Targeting homologous recombination and telomerase in Barrett's adenoCarcinoma: impact on telomere maintenance, genomic instability and tumor growth.
- CRM1 inhibition induces tumor Cell cytotoxicity and impairs osteoclastogenesis in multiple myeloma: molecular mechanisms and therapeutic implications.
- Phase 1 study of pomalidomide MTD, safety, and efficacy in patients with refractory multiple Myeloma who have received lenalidomide and bortezomib.
- canEvolve: A Web Portal for Integrative Oncogenomics.
- Minor clone provides a reservoir for relapse in multiple Myeloma.
- Heat shock protein 90 is critical for regulation of phenotype and functional activity of human T lymphocytes and NK Cells.
- MYD88 L265P in Waldenstrom's Macroglobulinemia, IgM Monoclonal Gammopathy, and other B-cell Lymphoproliferative Disorders using Conventional and Quantitative Allele-Sp...
- Tumor promoting immune suppressive Myeloid derived suppressor cells in multiple myeloma microenvironment.
- In vivo and in vitro effects of a novel anti-Dkk1 neutralizing antibody in multiple Myeloma.
- Endothelial stress products and Coagulation markers in patients with multiple myeloma treated with lenalidomide plus dexamethasone: an observational study.
- Canonical and noncanonical Hedgehog pathway in the pathogenesis of multiple Myeloma.
- A small molecule inhibitor of ubiquitin-specific protease-7 induces apoptosis in multiple myeloma Cells and overcomes bortezomib resistance.
- Myeloma-specific multiple peptides able to generate cytotoxic T lymphocytes: a potential therapeutic application in multiple myeloma and other plasma cell Disorders.
- Pathological crystallization of human immunoglobulins.
- A novel immunogenic CS1-specific peptide inducing antigen-specific cytotoxic T lymphocytes targeting multiple Myeloma.
- Potent in vitro and in vivo activity of an Fc-engineered humanized anti-HM1.24 antibody against multiple Myeloma via augmented effector function.
- Management of relapsed and relapsed/refractory multiple Myeloma.
- Novel epitope evoking CD138 antigen-specific cytotoxic T lymphocytes targeting multiple myeloma and other plasma cell Disorders.
- Significant biological role of Sp1 transactivation in multiple Myeloma.
- Vorinostat induced Cellular stress disrupts the p38 mitogen activated protein kinase and extraCellular signal regulated kinase pathways leading to apoptosis in Waldens...
- MGUS and smoldering myeloma: the most prevalent of plasma Cell dyscrasias.
- Chromothripsis identifies a rare and aggressive entity among newly diagnosed multiple Myeloma patients.
- AntiMyeloma Activity of a Multitargeted Kinase Inhibitor, AT9283, via Potent Aurora Kinase and STAT3 Inhibition Either Alone or in Combination with Lenalidomide.
- A phase I safety study of enzastaurin plus bortezomib in the treatment of relapsed or refractory multiple Myeloma.
- Genomics in multiple Myeloma.
- Histone deacetylase inhibitors demonstrate significant preclinical activity as single agents, and in combination with bortezomib in Waldenström's Macroglobulinemia.
- MicroRNAs 15a/16-1 function as tumor suppressor genes in multiple Myeloma.
- PI3K/p110{delta} is a novel therapeutic target in multiple Myeloma.
- Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple Myeloma.
- Elevated IL-17 produced by TH17 Cells promotes myeloma Cell growth and inhibits immune function in multiple myeloma.
- Mechanism of action of immunomodulatory agents in multiple Myeloma.
- A proto-oncogene BCL6 is up-regulated in the bone marrow microenvironment in multiple myeloma Cells.
- The sumoylation pathway is dysregulated in multiple Myeloma and is associated with adverse patient outcome.
- Tumor cell-specific bioluminescence platform to identify stroma-induced changes to antiCancer drug activity.
- Dual inhibition of akt/mammalian target of rapamycin pathway by nanoparticle albumin-bound-rapamycin and perifosine induces antitumor activity in multiple Myeloma.
- Tailoring treatment for multiple Myeloma patients with relapsed and refractory disease.
- AntiCancer activity of a broccoli derivative, sulforaphane, in barrett adenocarcinoma: potential use in chemoprevention and as adjuvant in chemotherapy.
- A high-affinity fully human anti-IL-6 mAb, 1339, for the treatment of multiple Myeloma.
- Interactions of the Hdm2/p53 and proteasome pathways may enhance the antitumor activity of bortezomib.
- Multicenter, phase I, dose-escalation trial of lenalidomide plus bortezomib for relapsed and relapsed/refractory multiple Myeloma.
- Identification of novel antigens with induced immune response in monoclonal gammopathy of undetermined significance.
- Novel therapies in the treatment of multiple Myeloma.
- Prognostic significance of copy-number alterations in multiple Myeloma.
- High-dose zoledronic acid impacts bone remodeling with effects on osteoblastic lineage and bone mechanical properties.
- Bortezomib induces canonical nuclear factor-kappaB activation in multiple myeloma Cells.
- Single-agent bortezomib in previously untreated multiple Myeloma: efficacy, characterization of peripheral neuropathy, and molecular correlations with response and neu...
- AntiMyeloma activity of the orally bioavailable dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235.
- Anti-DKK1 mAb (BHQ880) as a potential therapeutic agent for multiple Myeloma.
- Biologic sequelae of I{kappa}B kinase (IKK) inhibition in multiple Myeloma: therapeutic implications.
- Preclinical activity of P276-00, a novel small-molecule cyclin-dependent kinase inhibitor in the therapy of multiple Myeloma.
- CS1 promotes multiple myeloma Cell adhesion, clonogenic growth, and tumorigenicity via c-maf-mediated interactions with bone marrow stromal Cells.
- CXCR4 inhibitor AMD3100 disrupts the interaction of multiple myeloma Cells with the bone marrow microenvironment and enhances their sensitivity to therapy.
- Emerging treatments for multiple Myeloma: beyond immunomodulatory drugs and bortezomib.
- Dysfunctional homologous recombination mediates genomic instability and progression in Myeloma.
- Sinus tracts--an early sign of bisphosphonate-associated osteonecrosis of the jaws?
- Targeting PKC: a novel role for beta-catenin in ER stress and apoptotic signaling.
- Lenalidomide and rituximab in Waldenstrom's Macroglobulinemia.
- CD27-CD70 interactions in the pathogenesis of Waldenstrom Macroglobulinemia.
- Generation of antitumor invariant natural killer T Cell lines in multiple myeloma and promotion of their functions via lenalidomide: a strategy for immunotherapy.
- Lenalidomide inhibits osteoclastogenesis, survival factors and bone-remodeling markers in multiple Myeloma.
- Anti-CS1 humanized monoclonal antibody HuLuc63 inhibits myeloma Cell adhesion and induces antibody-dependent Cellular cytotoxicity in the bone marrow milieu.
Schools
Maharaja Krishna Chandra Gajapati Medical College Berhampur University
Shri Sayaji Genl Hospital Ms University
Ssg Hospital Ms University
In University Mc
Johns Hopkins Oncology Center
Procedures Preformed
- Cardiac MRI (Magnetic Resonance Imaging) of Heart or Chest
- Plasmapheresis
- Thoracentesis
Conditions Treated
- Acute Leukemia
- Anemia
- Bladder Cancer
- Breast Cancer
- View All
Doctors Specialties
- Medical Oncology
- Oncology
- Hematology
Accepted Insurances
Awards
- Super Doctor
Education
-
Indiana University School of Medicine -
Johns Hopkins University -
Baroda Medical College
Hospital
-
Brigham and Women's Hospital -
Massachusetts General Hospital -
Dana-Farber Cancer Institute
Drug Facts
| NPI NUMBER | 1912979212 | |
| NPPES Provider LastName | MUNSHI | |
| NPPES Provider FirstName | NIKHIL | |
| NPPES Provider ZIPCode | 02115 | |
| NPPES Provider State | MA | |
| Specialty Description | Medical Oncology | |
| Total Claim Count | 127.0 | |
| Distinct Opioid Count | 0.0 | |
| Opioid Claim Count | 0.0 | |
| Percent Opioid Claims | 0.0 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1912979212 |
| Last Name Of The Provider | MUNSHI |
| First Name Of The Provider | NIKHIL |
| View All |
Similar Doctors
|
|
Dr. Martha Wadleigh, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Anthony G. Letai, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Catherine J. Wu, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Lawrence N. Shulman, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Kala Seetharaman, MB
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Leonardo A. Sirulnik, MD |
|
|
Dr. Eric D. Jacobsen, MD
This Doctor is OpenDoctor Recommended.
|